The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Experimental Hematology & Oncology

Review

Jie Zhang¹  Tingxun Lu²  Zijun Y. Xu-Monette³  Ken H. Young³ 

[1] Department of Oncology, Affiliated Hospital of Jiangnan University, 214122, Wuxi, Jiangsu Province, China;Department of Oncology, Affiliated Hospital of Jiangnan University, 214122, Wuxi, Jiangsu Province, China;Division of Hematopathology, Department of Pathology, Duke University School of Medicine, 27710, Durham, NC, USA;Division of Hematopathology, Department of Pathology, Duke University School of Medicine, 27710, Durham, NC, USA;Duke Cancer Institute, 27710, Durham, NC, USA;

关键词: Diffuse large B-cell lymphoma;    Immunotherapy;    Radiotherapy;    Refractory;    Relapsed;   

DOI  :  10.1186/s40164-023-00432-z

 received in 2023-05-12, accepted in 2023-07-30,  发布年份 2023

来源: Springer

【 摘 要 】

Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-SCT). However, the patients who failed in salvage treatment or those ineligible for subsequent auto-SCT have dismal outcomes. Several immune-based therapies have been developed, including monoclonal antibodies, antibody–drug conjugates, bispecific T-cell engaging antibodies, chimeric antigen receptor T-cells, immune checkpoint inhibitors, and novel small molecules. Meanwhile, allogeneic SCT and radiotherapy are still necessary for disease control for fit patients with certain conditions. In this review, to expand clinical treatment options, we summarize the recent progress of immune-related therapies and prospect the future indirections in patients with R/R DLBCL.

【 授权许可】

CC BY   
© YUMED Inc. and BioMed Central Ltd. 2023

【 图 表 】

40517_2023_266_Article_IEq59.gif

Fig. 1

Fig. 6

Fig. 3

Fig. 9